Press releases
- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:FRA) traded at 78.50, -4.27% below its 52-week high of 82.00, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 78.50 |
---|---|
High | 78.50 |
Low | 78.50 |
Bid | 75.00 |
Offer | 78.00 |
Previous close | 78.50 |
Average volume | 6.67 |
---|---|
Shares outstanding | 17.96m |
Free float | 17.54m |
P/E (TTM) | 16.20 |
Market cap | 1.52bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:15 BST.
More ▼